2-Butoxyethyl trifluoromethanesulfonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 2-Butoxyethyl trifluoromethanesulfonate
• 英文别名: 2-butoxyethyl trifluoromethanesulfonate
• 化学式: C₇H₁₃F₃O₄S
• 分子量: 250.24
• InChiKey: HHBMRVOYTZBVCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE
  申请人：The Procter & Gamble Company

  公开号：US20170152222A1

  公开（公告）日：2017-06-01

  The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

  本发明提供了一种抑制胆碱或肉碱转化为三甲胺（TMA）并降低个体内TMAO水平的方法，包括向个体施用包含如公式（I）所示的化合物的组合物。本发明还提供了一种抑制细菌产生TMA的方法，包括向个体施用包含如公式（I）所示的化合物的组合物，其中所述化合物的施用量足以抑制个体内胆碱或肉碱形成三甲胺（TMA）。
• NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR
  申请人：Metabasis Therapeutics, Inc.

  公开号：US20160009639A1

  公开（公告）日：2016-01-14

  The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了公式（I）的新化合物及其药学上可接受的盐和共晶体，具有胰高血糖素受体拮抗剂或反向激动剂活性。本发明还提供了包括这些化合物的制药组合物，以及治疗、预防、延缓发病时间或减少胰高血糖素受体拮抗剂适用的一种或多种疾病或病情的发展或进展的方法，包括1型和2型糖尿病、胰岛素抵抗和高血糖。本发明还提供了制备公式I化合物，包括其盐和共晶体的方法，以及包括这些化合物的制药组合物。
• Antagonists of the glucagon receptor
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2786985A2

  公开（公告）日：2014-10-08

  The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as their use in methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia.

  本发明提供了具有胰高血糖素受体拮抗剂或反向激动剂活性的新型式 I 化合物及其药学上可接受的盐和共晶体。本发明进一步提供了包含这些化合物的药物组合物，以及它们在治疗、预防、推迟发病时间或降低疾病或病情发展或恶化风险的方法中的用途，这些疾病或病情适用于一种或多种胰高血糖素受体拮抗剂，包括 I 型和 II 型糖尿病、胰岛素抵抗和高血糖症。
• ANTAGONISTS OF THE GLUCAGON RECEPTOR
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2129654B1

  公开（公告）日：2014-05-28
• OXOPYRIDIN-DERIVATE ALS FAKTOR XIA HEMMER ZUR BEHANDLUNG VON THROMBOSE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3271332A1

  公开（公告）日：2018-01-24